Health reform is at a key juncture: What will happen in the Senate? President Trump may soon unveil a drug-pricing plan, and major FDA reforms are moving through Congress.

Sign up for 30 days of no-obligation access to Inside Health Policy for all the essential news during this critical time.

Latest News

Two Medicaid provisions in the Senate bill -- changes to the per-capita caps growth rate and provider taxes -- would decimate the skilled nursing sector, the lobby's CEO said in a briefing that came shortly after the American Medical Association told Senate leadership that the legislation would violate their oath to “first, do no harm.”

Anthem said Monday (June 26) that it believes the policies in the Senate GOP's draft health bill would “markedly improve” the stability of the individual market, but adds that it wants to work with Congress on Medicaid policy, mirroring a statement CEO Joseph Swedish made in reference to the House bill in March.

The Congressional Budget Office should estimate how many people would lose Medicaid coverage over 20 years of per-capita caps because Republicans are delaying the biggest cuts to Medicaid until near the end of the 10-year budget window to make the bill's impact on coverage appear smaller than they are, Senate Finance Committee ranking Democrat Ron Wyden (OR) said Monday (June 26).

A leaked draft of an alleged White House executive order on drug prices calls for value-based contracts, lower Medicare beneficiary out-of-pocket costs, drug rebate reforms, restricted hospital drug discounts, faster FDA approvals and higher prices in other countries.

Pfizer announced Thursday (June 22) that FDA has rejected its epoetin alfa biosimilar due to good manufacturing practice violations, despite an advisory committee recommending approval last month.

Democrats would likely use the Supreme Court ruling against mandatory Medicaid expansion to fight federal Medicaid funding caps, a former Senate Republican staffer said, but legal scholars doubt that suit would be a good precedent to use against the caps should the GOP health reform legislation be enacted.

CHICAGO -- A representative from pharmaceutical company Sarepta -- manufacturer of the controversial Duchenne muscular dystrophy drug Exondys 51 -- touted FDA's use of regulatory flexibility to approve Exondys 51, saying the approach has been frequently used for oncology drugs and could be a boon for the rare disease space.